抗病毒治疗与乙肝相关肝癌切除术后结局
该研究分析902例BCLC 0/A期HBV相关肝癌根治性切除患者,术后3个月内启动恩替卡韦、TDF或TAF治疗。IPTW调整后5年OS率分别为90.7%、95.2%、97.1%(整体p=0.079),5年RFS率无显著差异;多因素Cox回归显示TDF较ETV与更低死亡风险独立相关(aHR 0.48)。
要点
- 抗病毒方案选择与HBV相关肝癌切除术后RFS无显著关联
- TDF较ETV与更低的死亡风险独立相关(aHR 0.48)
- TAF生存率数值高于ETV但差异未达统计学显著
核心结论
- 抗病毒方案选择与HBV相关肝癌根治性切除术后RFS无关,而TDF较ETV与改善OS独立相关。
研究设计与样本
- 研究纳入902例BCLC 0或A期HBV相关肝癌根治性切除患者,术后3个月内接受ETV(n=474)、TDF(n=363)或TAF(n=65)一线治疗。
- 采用逆概率治疗加权(IPTW)平衡基线协变量,主要终点为OS,次要终点为RFS。
主要发现
- IPTW调整后5年OS率:ETV 90.7%、TDF 95.2%、TAF 97.1%(整体p=0.079)。
- 5年RFS率:ETV 57.4%、TDF 61.0%、TAF 69.4%(整体p=0.533)。
- 多因素Cox回归中,TDF较ETV与更低死亡风险独立相关(aHR 0.48;95%CI 0.26-0.89;p=0.021)。
- TAF较ETV生存率更高但未达统计学显著(aHR 0.34;95%CI 0.04-2.55;p=0.292)。
临床怎么用
- 对于HBV相关肝癌根治性切除术后患者,可优先考虑TDF以改善远期生存。
- 抗病毒方案选择不影响无复发生存,术后随访仍需关注肿瘤复发。
局限性
- TAF组样本量较小(n=65),其长期预后影响需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The comparative outcomes of entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF) in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) after curative resection remain unclear. This study aimed to evaluate the survival benefits of these antiviral regimens in a large real-world cohort. METHODS: We analysed 902 patients with BCLC stage 0 or A HBV-related HCC who underwent curative resection between September 2001 and August 2025. Patients received ETV (n = 474), TDF (n = 363), or TAF (n = 65) as first-line therapy within 3 months post-resection. Inverse probability of treatment weighting (IPTW) was implemented to balance baseline covariates. The primary and secondary endpoints were overall survival (OS) and recurrence-free survival (RFS). RESULTS: The IPTW-adjusted 5-year OS rates for ETV, TDF, and TAF were 90.7%, 95.2%, and 97.1%, respectively (global p = 0.079). The 5-year RFS rates were comparable for ETV, TDF, and TAF (57.4% vs. 61.0% vs. 69.4%; global p = 0.533). In multivariable Cox regression analysis, however, TDF was independently associated with a significantly lower risk of death compared with ETV (aHR 0.48; 95% CI, 0.26-0.89; p = 0.021). TAF showed higher survival rates compared to ETV, although the difference did not reach statistical significance (aHR 0.34; 95% CI, 0.04-2.55; p = 0.292). CONCLUSION: The choice of antiviral regimen was not associated with RFS after curative resection for HBV-related HCC, whereas TDF was independently associated with improved OS compared with ETV. Further large-scale studies are warranted to validate the long-term prognostic impact of TAF.
引用
- Jeong J, Hong JP, Kim DY, et al. Antiviral Therapy and Post-Resection Outcomes in Patients With Hepatitis B Virus-Related Hepatocellular Carcinoma. Aliment Pharmacol Ther. 2026. PMID: 42435007. doi:10.1111/apt.70850
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。